ArriVent BioPharma Company Insiders
| AVBP Stock | 24.06 -0.55 -2.23% |
ArriVent BioPharma's insiders are aggressively buying. The analysis of the overall insider sentiment regarding ArriVent BioPharma Common suggests that virtually all insiders are extremely bullish. ArriVent BioPharma employs about 77 people. The company is managed by 9 executives with a total tenure of roughly 180 years, averaging almost 20.0 years of service per executive, having 8.56 employees per reported executive.
Insider Sentiment
Aggressively Buying
Selling | Buying |
Latest Trades
| 2024-01-30 | Orbimed Advisors Llc | Acquired 444444 @ 18 | View |
Following insider trading sentiment in ArriVent BioPharma can help investors add context around confidence, timing, and operating risk while the public narrative is still evolving. The signal is still regulated and disclosed under securities law, which is why the public filing record matters more than rumor or interpretation alone.
ArriVent BioPharma has a market cap of 1.09 B, ROE of -58.88%. Use Trending Equities to explore allocation context. This includes a position in ArriVent BioPharma Common inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.ArriVent BioPharma Management Team Effectiveness
The company has return on total asset (ROA) of -36.49 % which means that it is not converting its asset base into profit. This is a lagging result relative to sector standards. Similarly, it shows a return on stockholder's equity (ROE) of -58.88 %, which means that it produced no profit with money invested by stockholders.This year, Common Stock Shares Outstanding is anticipated to decline to approximately 30.1 M
ArriVent Stock Ownership Analysis
About 96.0% of the company shares are held by institutions such as insurance companies. The book value of ArriVent BioPharma was presently reported as 7.24. The company recorded a loss per share of 4.32. ArriVent BioPharma Common had not issued any dividends in recent years.Reviewing share-based compensation in ArriVent BioPharma Common helps investors understand how management balances employee incentives against dilution risk. Shares outstanding are near 44.2 M. That is why investors should compare compensation intensity with revenue growth, margin progress, and free-cash-flow generation.
ArriVent BioPharma Quarterly Liabilities And Stockholders Equity | 333.17 Million |
Reviewing insider ownership in ArriVent BioPharma Common helps investors understand how much of the equity base is controlled by people involved in running the business. Insiders currently hold about 2.92% of outstanding shares. Investors usually want to know whether that level supports alignment without creating excessive control risk. View all of ArriVent BioPharma's insider trades
ArriVent BioPharma Common Insider Trading Activities
Insider trading disclosures for ArriVent BioPharma Common offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 1.09 Billion. Used properly, these records are better for context than for blind buy-or-sell signals.
ArriVent BioPharma Outstanding Bonds
Reviewing ArriVent BioPharma Common bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| ARROW ELECTRS INC Corp BondUS042735BF63 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| ARW 295 15 FEB 32 Corp BondUS04273WAC55 | View | |
| ARROW ELECTRS INC Corp BondUS042735AK67 | View |
ArriVent BioPharma Corporate Filings
13A | 5th of March 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 17th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 4th of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 3rd of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 30th of January 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 21st of January 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 14th of November 2025 An amended filing to the original Schedule 13G | ViewVerify |
8K | 10th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
ArriVent Stock Holders Distribution
Institutional ownership analysis for ArriVent BioPharma Common matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.
ArriVent BioPharma Market Cap and Value
ArriVent BioPharma Workforce Comparison
ArriVent BioPharma Common is rated below average. in number of employees category among its top competitors. The total workforce of Health Care industry is presently estimated at about 3,786. ArriVent BioPharma holds roughly 77.0 in number of employees claiming about 2.03% of equities under Health Care sector.
ArriVent BioPharma Insider Trading History
Insider trading disclosures for ArriVent BioPharma Common offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 1.09 Billion. Used properly, these records are better for context than for blind buy-or-sell signals.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-09-01 | 1.0 | 3 | 3 | 11,153 | 11,153 |
| 2024-03-01 | 1.0 | 12 | 12 | 9,226,636 | 63,909,387 |
ArriVent BioPharma Notable Stakeholders
Stakeholders matter for ArriVent BioPharma because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
| Zhengbin Yao | Chairman, CoFounder | Profile | |
| Stuart MD | President CoFounder | Profile | |
| Winston MBA | CFO Treasurer | Profile | |
| Robin MA | CoFounder COO | Profile | |
| Meghna Chowdary | Senior Strategy | Profile | |
| James JD | General Secretary | Profile | |
| Dandan Dong | Chief Officer | Profile | |
| Brent Rice | Chief Officer | Profile | |
| Yang Wang | Chief Officer | Profile |
About ArriVent BioPharma Management
ArriVent BioPharma is a mid-cap company in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Executive turnover can affect operating consistency and long-range planning. ArriVent BioPharma employs 77 people. 
Vlad Skutelnik ยท Macroaxis Contributor
Unless otherwise specified, financial data for ArriVent BioPharma Common is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. ArriVent BioPharma Common may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
ArriVent Stock is Curated By:
Vlad Skutelnik ยท Macroaxis ContributorWorkforce Efficiency and Productivity
Investors reviewing ArriVent BioPharma Common can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.
ArriVent BioPharma Manpower Efficiency
Return on ArriVent BioPharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 2.2M | |
| Net Loss Per Executive | 18.5M | |
| Working Capital Per Employee | 4M | |
| Working Capital Per Executive | 34.1M |
Additional Tools for ArriVent Stock Analysis
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |